Incyte (INCY) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Incyte (NASDAQ: INCY) recently:

• 2/12/2025 – Incyte was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 2/11/2025 – Incyte had its price target lowered by analysts at Royal Bank of Canada from $70.00 to $68.00. They now have a “sector perform” rating on the stock.
• 2/11/2025 – Incyte had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 2/11/2025 – Incyte had its price target lowered by analysts at Citigroup Inc. from $97.00 to $88.00. They now have a “buy” rating on the stock.
• 2/10/2025 – Incyte had its price target raised by analysts at Stifel Nicolaus from $75.00 to $77.00. They now have a “hold” rating on the stock.
• 2/4/2025 – Incyte was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 1/23/2025 – Incyte had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $70.00 price target on the stock.
• 1/14/2025 – Incyte had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 1/10/2025 – Incyte had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald.
• 12/19/2024 – Incyte had its price target raised by analysts at Wells Fargo & Company from $68.00 to $70.00. They now have an “equal weight” rating on the stock.
• 12/17/2024 – Incyte is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $77.00 price target on the stock.

Incyte Stock Performance

Shares of NASDAQ:INCY opened at $70.01 on Friday. The business has a fifty day moving average of $71.47 and a 200-day moving average of $69.16. The firm has a market cap of $13.49 billion, a PE ratio of 500.11, a price-to-earnings-growth ratio of 0.53 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.82 and a current ratio of 1.87. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. On average, equities research analysts predict that Incyte Co. will post 0.35 EPS for the current fiscal year.

Insider Activity at Incyte

In other news, EVP Vijay K. Iyengar sold 6,043 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $75.38, for a total transaction of $455,521.34. Following the transaction, the executive vice president now owns 30,658 shares of the company’s stock, valued at $2,311,000.04. This represents a 16.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Steven H. Stein sold 12,352 shares of Incyte stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total value of $897,866.88. Following the completion of the sale, the executive vice president now owns 66,967 shares of the company’s stock, valued at approximately $4,867,831.23. The trade was a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 19,695 shares of company stock valued at $1,444,356 over the last quarter. Corporate insiders own 17.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of INCY. Haverford Trust Co raised its stake in shares of Incyte by 1.8% during the third quarter. Haverford Trust Co now owns 7,796 shares of the biopharmaceutical company’s stock worth $515,000 after buying an additional 135 shares during the last quarter. Retirement Systems of Alabama grew its holdings in Incyte by 0.4% during the 4th quarter. Retirement Systems of Alabama now owns 34,620 shares of the biopharmaceutical company’s stock worth $2,391,000 after acquiring an additional 139 shares during the period. V Square Quantitative Management LLC raised its position in shares of Incyte by 4.1% during the 3rd quarter. V Square Quantitative Management LLC now owns 3,963 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 155 shares during the last quarter. Trust Point Inc. lifted its stake in shares of Incyte by 5.0% in the 4th quarter. Trust Point Inc. now owns 3,282 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 156 shares during the period. Finally, Bank of Nova Scotia lifted its stake in shares of Incyte by 0.8% in the 4th quarter. Bank of Nova Scotia now owns 21,694 shares of the biopharmaceutical company’s stock valued at $1,498,000 after purchasing an additional 171 shares during the period. Institutional investors own 96.97% of the company’s stock.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.